{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T22:10:20Z","timestamp":1648851020448},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2010,7,30]],"date-time":"2010-07-30T00:00:00Z","timestamp":1280448000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z. Rheumatol."],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1007\/s00393-010-0635-z","type":"journal-article","created":{"date-parts":[[2010,7,28]],"date-time":"2010-07-28T19:20:59Z","timestamp":1280344859000},"page":"505-515","source":"Crossref","is-referenced-by-count":4,"title":["Die Bedeutung von Biologika bei der Therapie der SoJIA (Morbus Still)"],"prefix":"10.1007","volume":"69","author":[{"given":"G.","family":"D\u00fcckers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Niehues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,7,30]]},"reference":[{"key":"635_CR1","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jaci.2005.07.020","volume":"116","author":"Ballow","year":"2005","unstructured":"Ballow M (2005) -ximab this and -zumab that! Has the magic bullet arrived in the new millennium of medicine and science? J Allergy Clin Immunol 116:738\u2013743","journal-title":"J Allergy Clin Immunol"},{"key":"635_CR2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1546-0096-7-21","volume":"7","author":"Canna","year":"2009","unstructured":"Canna S, Frankovich J, Higgins G et al (2009) Acute hepatitis in three patients with systemic juvenile idiopathic arthritis taking interleukin-1 receptor antagonist. Pediatr Rheumatol Online J 7:21","journal-title":"Pediatr Rheumatol Online J"},{"key":"635_CR3","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1182\/blood-2006-03-014126","volume":"108","author":"Carta","year":"2006","unstructured":"Carta S, Tassi S, Semino C et al (2006) Histone deacetylase inhibitors prevent exocytosis of interleukin-1beta-containing secretory lysosomes: role of microtubules. Blood 108:1618\u20131626","journal-title":"Blood"},{"key":"635_CR4","unstructured":"Cassidy JT, Petty RE (2005) Juvenile idiopathic rheumatic arthritis. WB Saunders, Philadelphia"},{"key":"635_CR5","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/BOR.0b013e32832f1445","volume":"21","author":"De","year":"2009","unstructured":"De Benedetti F (2009) Targeting interleukin-6 in pediatric rheumatic diseases. Curr Opin Rheumatol 21:533\u2013537","journal-title":"Curr Opin Rheumatol"},{"key":"635_CR6","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/art.1780340912","volume":"34","author":"De","year":"1991","unstructured":"De Benedetti F, Massa M, Robbioni P et al (1991) Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 34:1158\u20131163","journal-title":"Arthritis Rheum"},{"key":"635_CR7","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/ard.2006.061853","volume":"66","author":"De","year":"2007","unstructured":"De Jager W, Hoppenreijs EP, Wulffraat NM et al (2007) Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann Rheum Dis 66:589\u2013598","journal-title":"Ann Rheum Dis"},{"key":"635_CR8","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/RHU.0b013e3181ba3c6f","volume":"15","author":"Feito","year":"2009","unstructured":"Feito JG, Pereda CA (2009) Rituximab therapy produced rapid and sustained clinical improvement in a patient with systemic onset juvenile idiopathic arthritis refractory to TNF alpha antagonists. J Clin Rheumatol 15:363\u2013365","journal-title":"J Clin Rheumatol"},{"key":"635_CR9","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1097\/01.rhu.0000166673.34461.33","volume":"11","author":"Firestein","year":"2005","unstructured":"Firestein GS (2005) Immunologic mechanisms in the pathogenesis of rheumatoid arthritis. J Clin Rheumatol 11:S39\u2013S44","journal-title":"J Clin Rheumatol"},{"key":"635_CR10","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.0906-6705.2005.00271.x","volume":"14","author":"Frosch","year":"2005","unstructured":"Frosch M, Metze D, Foell D et al (2005) Early activation of cutaneous vessels and epithelial cells is characteristic of acute systemic onset juvenile idiopathic arthritis. Exp Dermatol 14:259\u2013265","journal-title":"Exp Dermatol"},{"key":"635_CR11","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/art.23437","volume":"58","author":"Gattorno","year":"2008","unstructured":"Gattorno M, Piccini A, Lasiglie D et al (2008) The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 58:1505\u20131515","journal-title":"Arthritis Rheum"},{"key":"635_CR12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s10067-007-0743-6","volume":"27","author":"Golmia","year":"2008","unstructured":"Golmia A, Grinblat B, Finger E et al (2008) The development of erythema elevatum diutinum in a patient with juvenile idiopathic arthritis under treatment with abatacept. Clin Rheumatol 27:105\u2013106","journal-title":"Clin Rheumatol"},{"key":"635_CR13","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.4049\/jimmunol.0901467","volume":"184","author":"Grabiec","year":"2010","unstructured":"Grabiec AM, Krausz S, De Jager W et al (2010) Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue. J Immunol 184:2718\u20132728","journal-title":"J Immunol"},{"key":"635_CR14","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1055\/s-0028-1086037","volume":"220","author":"Guellac","year":"2008","unstructured":"Guellac N, Niehues T (2008) Interdisciplinary and evidence-based treatment guideline for juvenile idiopathic arthritis. Klin Padiatr 220:392\u2013402","journal-title":"Klin Padiatr"},{"key":"635_CR15","first-page":"758","volume":"25","author":"Guignard","year":"2007","unstructured":"Guignard S, Dien G, Dougados M (2007) Severe systemic inflammatory response syndrome in a patient with adult onset Still\u2019s disease treated with the anti-IL1 drug anakinra: a case report. Clin Exp Rheumatol 25:758\u2013759","journal-title":"Clin Exp Rheumatol"},{"key":"635_CR16","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1002\/art.23687","volume":"58","author":"Hoffman","year":"2008","unstructured":"Hoffman HM, Throne MI, Amar NJ et al (2008) Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 58:2443\u20132452","journal-title":"Arthritis Rheum"},{"key":"635_CR17","first-page":"326","volume":"31","author":"Horneff","year":"2008","unstructured":"Horneff G, Augustin S (2008) Medical treatment of juvenile idiopathic arthritis. Med Monatsschr Pharm 31:326\u2013336; quiz 337\u2013328","journal-title":"Med Monatsschr Pharm"},{"key":"635_CR18","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1136\/ard.2007.087593","volume":"68","author":"Horneff","year":"2009","unstructured":"Horneff G, De Bock F, Foeldvari I et al (2009) Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis 68:519\u2013525","journal-title":"Ann Rheum Dis"},{"key":"635_CR19","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s003930070043","volume":"59","author":"Horneff","year":"2000","unstructured":"Horneff G, Forster J, Seyberth HW et al (2000) Recommendations by the Pediatric and Adolescent Rheumatology Study Committee on therapy with etanercept (p75 tnf-alpha receptor immunoglobulin fusion protein. Pharmacotherapy Committee). Z Rheumatol 59:365\u2013369","journal-title":"Z Rheumatol"},{"key":"635_CR20","unstructured":"Horneff G, Hospach T, Dannecker G et al (2010) Updated statement by the German Society for Pediatric and Adolescent Rheumatology (GKJR) on the FDA\u2019s report regarding malignancies in anti-TNF-treated patients from. Z Rheumatol [Epub ahead of print]"},{"key":"635_CR21","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1136\/ard.2003.014886","volume":"63","author":"Horneff","year":"2004","unstructured":"Horneff G, Schmeling H, Biedermann T et al (2004) The German Etanercept Registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 63:1638\u20131644","journal-title":"Ann Rheum Dis"},{"key":"635_CR22","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s10067-008-0995-9","volume":"28","author":"Ilowite","year":"2009","unstructured":"Ilowite N, Porras O, Reiff A et al (2009) Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol 28:129\u2013137","journal-title":"Clin Rheumatol"},{"key":"635_CR23","doi-asserted-by":"crossref","unstructured":"Kasher-Meron M, Uziel Y, Amital H (2009) Successful treatment with B-cell depleting therapy for refractory systemic onset juvenile idiopathic arthritis: a case report. Rheumatology (Oxford) 48:445\u2013446","DOI":"10.1093\/rheumatology\/ken492"},{"key":"635_CR24","first-page":"119","volume":"25","author":"Kone-Paut","year":"2007","unstructured":"Kone-Paut I, Retornaz K, Garnier JM et al (2007) Visceral leishmaniasis in a patient with systemic juvenile arthritis treated by IL-1RA agonist (anakinra). Clin Exp Rheumatol 25:119","journal-title":"Clin Exp Rheumatol"},{"key":"635_CR25","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa0810787","volume":"360","author":"Lachmann","year":"2009","unstructured":"Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB et al (2009) Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 360:2416\u20132425","journal-title":"N Engl J Med"},{"key":"635_CR26","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1600-6143.2005.00749.x","volume":"5","author":"Larsen","year":"2005","unstructured":"Larsen CP, Pearson TC, Adams AB et al (2005) Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 5:443\u2013453","journal-title":"Am J Transplant"},{"key":"635_CR27","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S0140-6736(08)60999-X","volume":"372","author":"Lehman","year":"2008","unstructured":"Lehman TJ (2008) Are withdrawal trials in paediatric rheumatic disease helpful? Lancet 372:348\u2013350","journal-title":"Lancet"},{"key":"635_CR28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2119\/2006-00005.Dinarello","volume":"11","author":"Leoni","year":"2005","unstructured":"Leoni F, Fossati G, Lewis EC et al (2005) The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med 11:1\u201315","journal-title":"Mol Med"},{"key":"635_CR29","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1073\/pnas.052702999","volume":"99","author":"Leoni","year":"2002","unstructured":"Leoni F, Zaliani A, Bertolini G et al (2002) The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci U S A 99:2995\u20133000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"635_CR30","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/ard.2007.076034","volume":"67","author":"Lequerre","year":"2008","unstructured":"Lequerre T, Quartier P, Rosellini D et al (2008) Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 67:302\u2013308","journal-title":"Ann Rheum Dis"},{"key":"635_CR31","doi-asserted-by":"crossref","first-page":"S325","DOI":"10.1002\/art.21556","volume":"54","author":"Lovell","year":"2006","unstructured":"Lovell DJ, Giannini EH, Kimura Y et al (2006) Preliminary evidence for bioactivity of IL-1 trap (Rilonacept), a long acting IL-1 inhibtor, in systemic juvenile idiopathic arthritis (sJIA). Arthritis Rheum 54:S325","journal-title":"Arthritis Rheum"},{"key":"635_CR32","first-page":"S514","volume":"56","author":"Lovell","year":"2007","unstructured":"Lovell DJ, Giannini EH, Kimura Y et al (2007) Preliminary evidence for sustained bioactivity of IL-1 trap (rilonacept), a long acting IL-1 inhibitor, in systemic juvenile idiopathic arthritis. Arthritis Rheum 56:S514","journal-title":"Arthritis Rheum"},{"key":"635_CR33","first-page":"S768","volume":"60","author":"Lovell","year":"2009","unstructured":"Lovell DJ, Giannini EH, Kimura Y et al (2009) Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis (SJIA). Arthritis Rheum 60 (Suppl):S768 (abstr 2053)","journal-title":"Arthritis Rheum"},{"key":"635_CR34","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","volume":"342","author":"Lovell","year":"2000","unstructured":"Lovell DJ, Giannini EH, Reiff A et al (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 342:763\u2013769","journal-title":"N Engl J Med"},{"key":"635_CR35","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/art.23427","volume":"58","author":"Lovell","year":"2008","unstructured":"Lovell DJ, Reiff A, Ilowite NT et al (2008) Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 58:1496\u20131504","journal-title":"Arthritis Rheum"},{"key":"635_CR36","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","volume":"359","author":"Lovell","year":"2008","unstructured":"Lovell DJ, Ruperto N, Goodman S et al (2008) Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 359:810\u2013820","journal-title":"N Engl J Med"},{"key":"635_CR37","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.clim.2009.09.010","volume":"134","author":"Macaubas","year":"2010","unstructured":"Macaubas C, Nguyen K, Deshpande C et al (2010) Distribution of circulating cells in systemic juvenile idiopathic arthritis across disease activity states. Clin Immunol 134:206\u2013216","journal-title":"Clin Immunol"},{"key":"635_CR38","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1146\/annurev.immunol.021908.132715","volume":"27","author":"Martinon","year":"2009","unstructured":"Martinon F, Mayor A, Tschopp J (2009) The inflammasomes: guardians of the body. Annu Rev Immunol 27:229\u2013265","journal-title":"Annu Rev Immunol"},{"key":"635_CR39","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1146\/annurev.immunol.25.022106.141627","volume":"27","author":"Masters","year":"2009","unstructured":"Masters SI, Simon A, Aksentijevich I et al (2009) Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol 27:621\u2013668","journal-title":"Annu Rev Immunol"},{"key":"635_CR40","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/08916930902832306","volume":"42","author":"Morbach","year":"2009","unstructured":"Morbach H, Girschick HJ (2009) Do B cells play a role in the pathogenesis of juvenile idiopathic arthritis? Autoimmunity 42:373\u2013375","journal-title":"Autoimmunity"},{"key":"635_CR41","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1136\/ard.2008.092106","volume":"68","author":"Narvaez","year":"2009","unstructured":"Narvaez J, Diaz-Torne C, Juanola X et al (2009) Rituximab therapy for refractory systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis 68:607\u2013608","journal-title":"Ann Rheum Dis"},{"key":"635_CR42","doi-asserted-by":"crossref","unstructured":"Ohlsson V, Baildam E, Foster H et al (2008) Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA). Rheumatology (Oxford) 47:555\u2013556","DOI":"10.1093\/rheumatology\/ken030"},{"key":"635_CR43","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1084\/jem.20050473","volume":"201","author":"Pascual","year":"2005","unstructured":"Pascual V, Allantaz F, Arce E et al (2005) Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 201:1479\u20131486","journal-title":"J Exp Med"},{"key":"635_CR44","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/ard.2007.087411","volume":"68","author":"Prince","year":"2009","unstructured":"Prince FH, Twilt M, Ten Cate R et al (2009) Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch National Register. Ann Rheum Dis 68:635\u2013641","journal-title":"Ann Rheum Dis"},{"key":"635_CR45","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/art.10885","volume":"48","author":"Quartier","year":"2003","unstructured":"Quartier P, Taupin P, Bourdeaut F et al (2003) Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 48:1093\u20131101","journal-title":"Arthritis Rheum"},{"key":"635_CR46","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.22838","volume":"56","author":"Ruperto","year":"2007","unstructured":"Ruperto N, Lovell DJ, Cuttica R et al (2007) A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 56:3096\u20133106","journal-title":"Arthritis Rheum"},{"key":"635_CR47","doi-asserted-by":"crossref","unstructured":"Ruperto N, Lovell DJ, Quartier P et al (2010) Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum [Epub ahead of print]","DOI":"10.1002\/art.27431"},{"key":"635_CR48","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","volume":"372","author":"Ruperto","year":"2008","unstructured":"Ruperto N, Lovell DJ, Quartier P et al (2008) Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 372:383\u2013391","journal-title":"Lancet"},{"key":"635_CR49","first-page":"170","volume":"68","author":"Ruperto","year":"2009","unstructured":"Ruperto N, Quartier P, Wulffraat N et al (2009) A phase II trial with canakinumab (ACZ885), a new IL-1-beta blocking monoclonal antibody, to evaluate safety and preliminary efficacy in children with systemic juvenile idiopathic arthritis. Ann Rheum Dis 68:170","journal-title":"Ann Rheum Dis"},{"key":"635_CR50","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","volume":"357","author":"Sandborn","year":"2007","unstructured":"Sandborn WJ, Feagan BG, Stoinov S et al (2007) Certolizumab pegol for the treatment of Crohn\u2019s disease. N Engl J Med 357:228\u2013238","journal-title":"N Engl J Med"},{"key":"635_CR51","first-page":"CD008341","volume":"Rev","author":"Singh","year":"2010","unstructured":"Singh JA, Noorbaloochi S, Singh G (2010) Golimumab for rheumatoid arthritis. Cochrane Database Syst Rev:CD008341","journal-title":"Cochrane Database Syst"},{"key":"635_CR52","doi-asserted-by":"crossref","unstructured":"Tamary H, Roganovic J, Chitlur M et al (2010) Consensus Paper-ICIS Expert Meeting Basel 2009 treatment milestones in immune thrombocytopenia. Ann Hematol [Epub ahead of print]","DOI":"10.1007\/s00277-010-0941-1"},{"key":"635_CR53","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/j.1651-2227.2010.01771.x","volume":"99","author":"Tullus","year":"2010","unstructured":"Tullus K (2010) Modern therapeutic strategies for paediatric systemic lupus erythematosus and lupus nephritis. Acta Paediatr 99:967\u2013974","journal-title":"Acta Paediatr"},{"key":"635_CR54","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.cyto.2009.07.391","volume":"48","author":"Vojinovic","year":"2009","unstructured":"Vojinovic J, Dinarello CA, Furlan A et al (2009) Safety and efficacy of oral ITF2357 in patients with active systemic onset juvenile idiopathic arthritis. Cytokine 48:93\u201394","journal-title":"Cytokine"},{"key":"635_CR55","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/art.22070","volume":"54","author":"Weinblatt","year":"2006","unstructured":"Weinblatt M, Combe B, Covucci A et al (2006) Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis Rheum 54:2807\u20132816","journal-title":"Arthritis Rheum"},{"key":"635_CR56","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1002\/art.24137","volume":"58","author":"Wittkowski","year":"2008","unstructured":"Wittkowski H, Frosch M, Wulffraat N et al (2008) S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis Rheum 58:3924\u20133931","journal-title":"Arthritis Rheum"},{"key":"635_CR57","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/ncprheum0084","volume":"2","author":"Woo","year":"2006","unstructured":"Woo P (2006) Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome. Nat Clin Pract Rheumatol 2:28\u201334","journal-title":"Nat Clin Pract Rheumatol"},{"key":"635_CR58","doi-asserted-by":"crossref","first-page":"R1281","DOI":"10.1186\/ar1826","volume":"7","author":"Woo","year":"2005","unstructured":"Woo P, Wilkinson N, Prieur AM et al (2005) Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther 7:R1281\u2013R1288","journal-title":"Arthritis Res Ther"},{"key":"635_CR59","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","volume":"371","author":"Yokota","year":"2008","unstructured":"Yokota S, Imagawa T, Mori M et al (2008) Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 371:998\u20131006","journal-title":"Lancet"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-010-0635-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-010-0635-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-010-0635-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T16:36:02Z","timestamp":1559061362000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-010-0635-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,30]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["635"],"URL":"https:\/\/doi.org\/10.1007\/s00393-010-0635-z","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,30]]}}}